论文部分内容阅读
评价阿奇霉素治疗细菌性感染的疗效与安全性。采用随机对照多中心分组研究方法 ,将 94例下呼吸道感染病人随机分为 2组 (每组 47例 )。试验组用阿奇霉素 0 .5 g加入 5 %葡萄糖注射液 5 0 0 ml静脉滴注 ,qd,5～ 7d为一个疗程 ;对照组用乳糖酸红霉素 0 .5 g加入 5 %葡萄糖注射液 5 0 0 ml静脉滴注 ,bid,5～ 7d为一个疗程。另 12例 (4例盆腔炎和 8例下呼吸道感染 )为开放组 ,以阿奇霉素治疗。结果 ,试验组痊愈率(6 1.7% )、有效率 (91.5 % )、及细菌清除率 (95 .8% )均极显著高于对照组 (31.9%、70 .2 %、76 .6 % )。以阿奇霉素治疗的 5 9例患者 ,总有效率为 93.2 % ,痊愈率 6 2 .7%。试验组不良反应率为 12 .8% ,亦显著低于对照组(34.0 % )。结论 :阿奇霉素是治疗院外获得性呼吸道与泌尿生殖道感染的有效和安全的药物。
To evaluate the efficacy and safety of azithromycin in the treatment of bacterial infections. Ninety - four patients with lower respiratory tract infection were randomly divided into two groups (n = 47 in each group) using a randomized controlled multicenter study. The experimental group with azithromycin 0.5g 5% glucose injection by 500 ml intravenous infusion, qd, 5 ~ 7d for a course of treatment; control group with erythromycin lactobionate 0.5g 5% glucose injection 5 0 0 ml intravenous infusion, bid, 5 ~ 7d for a course of treatment. The other 12 cases (4 cases of pelvic inflammatory disease and 8 cases of lower respiratory tract infection) were open to azithromycin treatment. Results The cure rate (61.7%), effective rate (91.5%) and bacterial clearance rate (95.8%) in the experimental group were significantly higher than those in the control group (31.9%, 70.2%, 76.6%) . Among the 59 patients treated with azithromycin, the total effective rate was 93.2% and the cure rate was 62.7%. Adverse reaction rate in the experimental group was 12.8%, which was also significantly lower than that in the control group (34.0%). Conclusion: Azithromycin is an effective and safe drug for the treatment of acquired respiratory and urogenital infections in the hospital.